Sesame oil as a potential therapeutic agent against nutritional steatohepatitis

Srinivasan Periasamy, Ming-Yi Liu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the general population. Nonalcoholic steatohepatitis (NASH), also called nutritional steatohepatitis and nutritional fibrosing steatohepatitis, can progress to liver failure and hepatocellular carcinoma. Nutritional fibrosing steatohepatitis has been called "a tale of a twohit hypothesis": the "First Hit" is characterized by hepatic injury and fat accumulation, and the "Second Hit" is characterized by hepatic oxidative stress, inflammation, and insulin resistance. Managing NAFLD focuses particularly on diet and exercise; managing NASH focuses on lifestyle modifications, control of associated metabolic issues, and pharmacological therapy for liver injury. Successful care and treatment require an integrative approach. Proposed pharmacological therapies for NASH include vitamin E, ursodeoxycholic acid (a drug used to dissolve gallstones), pioglitazone (one of a class of drugs called thiazolidinediones that are used to treat type 2 diabetes), and metformin (used to treat type 2 diabetes); however, drugs are therapeutically limited and may produce adverse effects. The search for a novel and effective medication to treat nutritional steatohepatitis continues. Sesame oil is nontoxic, antioxidant-rich, and nutritional oil, and it is effective against various diseases models; it attenuates both the first and second hits of nutritional steatohepatitis. Sesame oil attenuates hepatic injury and steatosis, reduces levels of triglycerides, nitric oxide, malondialdehyde (a biomarker of lipid peroxidation), tumor necrosis factor-α, interleukin-6, interleukin-1β, leptin, tissue growth factor-β1, α-smooth muscle actin, fibrosis, and the activity of matrix metalloproteinase-2 and -9, but it increases tissue inhibitor of metalloproteinases-1 and peroxisomal proliferator-activated receptor-γ expression. Thus, we hypothesize that sesame oil would be useful for treating NASH.

Original languageEnglish
Title of host publicationSeed Oil
Subtitle of host publicationBiological Properties, Health Benefits and Commercial Applications
PublisherNova Science Publishers, Inc.
Pages131-148
Number of pages18
ISBN (Electronic)9781634630955
ISBN (Print)9781634630566
Publication statusPublished - 2014 Jan 1

Fingerprint

Sesame Oil
sesame oil
Fatty Liver
therapeutics
liver
fatty liver
noninsulin-dependent diabetes mellitus
drugs
ursodeoxycholic acid
pioglitazone
Liver
metformin
cholelithiasis
liver failure
Type 2 Diabetes Mellitus
gelatinase A
disease models
tumor necrosis factors
interleukin-1
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Agricultural and Biological Sciences(all)

Cite this

Periasamy, S., & Liu, M-Y. (2014). Sesame oil as a potential therapeutic agent against nutritional steatohepatitis. In Seed Oil: Biological Properties, Health Benefits and Commercial Applications (pp. 131-148). Nova Science Publishers, Inc..
Periasamy, Srinivasan ; Liu, Ming-Yi. / Sesame oil as a potential therapeutic agent against nutritional steatohepatitis. Seed Oil: Biological Properties, Health Benefits and Commercial Applications. Nova Science Publishers, Inc., 2014. pp. 131-148
@inbook{18ac6219ba994240a9a8632f57b88fb9,
title = "Sesame oil as a potential therapeutic agent against nutritional steatohepatitis",
abstract = "Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the general population. Nonalcoholic steatohepatitis (NASH), also called nutritional steatohepatitis and nutritional fibrosing steatohepatitis, can progress to liver failure and hepatocellular carcinoma. Nutritional fibrosing steatohepatitis has been called {"}a tale of a twohit hypothesis{"}: the {"}First Hit{"} is characterized by hepatic injury and fat accumulation, and the {"}Second Hit{"} is characterized by hepatic oxidative stress, inflammation, and insulin resistance. Managing NAFLD focuses particularly on diet and exercise; managing NASH focuses on lifestyle modifications, control of associated metabolic issues, and pharmacological therapy for liver injury. Successful care and treatment require an integrative approach. Proposed pharmacological therapies for NASH include vitamin E, ursodeoxycholic acid (a drug used to dissolve gallstones), pioglitazone (one of a class of drugs called thiazolidinediones that are used to treat type 2 diabetes), and metformin (used to treat type 2 diabetes); however, drugs are therapeutically limited and may produce adverse effects. The search for a novel and effective medication to treat nutritional steatohepatitis continues. Sesame oil is nontoxic, antioxidant-rich, and nutritional oil, and it is effective against various diseases models; it attenuates both the first and second hits of nutritional steatohepatitis. Sesame oil attenuates hepatic injury and steatosis, reduces levels of triglycerides, nitric oxide, malondialdehyde (a biomarker of lipid peroxidation), tumor necrosis factor-α, interleukin-6, interleukin-1β, leptin, tissue growth factor-β1, α-smooth muscle actin, fibrosis, and the activity of matrix metalloproteinase-2 and -9, but it increases tissue inhibitor of metalloproteinases-1 and peroxisomal proliferator-activated receptor-γ expression. Thus, we hypothesize that sesame oil would be useful for treating NASH.",
author = "Srinivasan Periasamy and Ming-Yi Liu",
year = "2014",
month = "1",
day = "1",
language = "English",
isbn = "9781634630566",
pages = "131--148",
booktitle = "Seed Oil",
publisher = "Nova Science Publishers, Inc.",

}

Periasamy, S & Liu, M-Y 2014, Sesame oil as a potential therapeutic agent against nutritional steatohepatitis. in Seed Oil: Biological Properties, Health Benefits and Commercial Applications. Nova Science Publishers, Inc., pp. 131-148.

Sesame oil as a potential therapeutic agent against nutritional steatohepatitis. / Periasamy, Srinivasan; Liu, Ming-Yi.

Seed Oil: Biological Properties, Health Benefits and Commercial Applications. Nova Science Publishers, Inc., 2014. p. 131-148.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Sesame oil as a potential therapeutic agent against nutritional steatohepatitis

AU - Periasamy, Srinivasan

AU - Liu, Ming-Yi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the general population. Nonalcoholic steatohepatitis (NASH), also called nutritional steatohepatitis and nutritional fibrosing steatohepatitis, can progress to liver failure and hepatocellular carcinoma. Nutritional fibrosing steatohepatitis has been called "a tale of a twohit hypothesis": the "First Hit" is characterized by hepatic injury and fat accumulation, and the "Second Hit" is characterized by hepatic oxidative stress, inflammation, and insulin resistance. Managing NAFLD focuses particularly on diet and exercise; managing NASH focuses on lifestyle modifications, control of associated metabolic issues, and pharmacological therapy for liver injury. Successful care and treatment require an integrative approach. Proposed pharmacological therapies for NASH include vitamin E, ursodeoxycholic acid (a drug used to dissolve gallstones), pioglitazone (one of a class of drugs called thiazolidinediones that are used to treat type 2 diabetes), and metformin (used to treat type 2 diabetes); however, drugs are therapeutically limited and may produce adverse effects. The search for a novel and effective medication to treat nutritional steatohepatitis continues. Sesame oil is nontoxic, antioxidant-rich, and nutritional oil, and it is effective against various diseases models; it attenuates both the first and second hits of nutritional steatohepatitis. Sesame oil attenuates hepatic injury and steatosis, reduces levels of triglycerides, nitric oxide, malondialdehyde (a biomarker of lipid peroxidation), tumor necrosis factor-α, interleukin-6, interleukin-1β, leptin, tissue growth factor-β1, α-smooth muscle actin, fibrosis, and the activity of matrix metalloproteinase-2 and -9, but it increases tissue inhibitor of metalloproteinases-1 and peroxisomal proliferator-activated receptor-γ expression. Thus, we hypothesize that sesame oil would be useful for treating NASH.

AB - Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in the general population. Nonalcoholic steatohepatitis (NASH), also called nutritional steatohepatitis and nutritional fibrosing steatohepatitis, can progress to liver failure and hepatocellular carcinoma. Nutritional fibrosing steatohepatitis has been called "a tale of a twohit hypothesis": the "First Hit" is characterized by hepatic injury and fat accumulation, and the "Second Hit" is characterized by hepatic oxidative stress, inflammation, and insulin resistance. Managing NAFLD focuses particularly on diet and exercise; managing NASH focuses on lifestyle modifications, control of associated metabolic issues, and pharmacological therapy for liver injury. Successful care and treatment require an integrative approach. Proposed pharmacological therapies for NASH include vitamin E, ursodeoxycholic acid (a drug used to dissolve gallstones), pioglitazone (one of a class of drugs called thiazolidinediones that are used to treat type 2 diabetes), and metformin (used to treat type 2 diabetes); however, drugs are therapeutically limited and may produce adverse effects. The search for a novel and effective medication to treat nutritional steatohepatitis continues. Sesame oil is nontoxic, antioxidant-rich, and nutritional oil, and it is effective against various diseases models; it attenuates both the first and second hits of nutritional steatohepatitis. Sesame oil attenuates hepatic injury and steatosis, reduces levels of triglycerides, nitric oxide, malondialdehyde (a biomarker of lipid peroxidation), tumor necrosis factor-α, interleukin-6, interleukin-1β, leptin, tissue growth factor-β1, α-smooth muscle actin, fibrosis, and the activity of matrix metalloproteinase-2 and -9, but it increases tissue inhibitor of metalloproteinases-1 and peroxisomal proliferator-activated receptor-γ expression. Thus, we hypothesize that sesame oil would be useful for treating NASH.

UR - http://www.scopus.com/inward/record.url?scp=84956608028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956608028&partnerID=8YFLogxK

M3 - Chapter

SN - 9781634630566

SP - 131

EP - 148

BT - Seed Oil

PB - Nova Science Publishers, Inc.

ER -

Periasamy S, Liu M-Y. Sesame oil as a potential therapeutic agent against nutritional steatohepatitis. In Seed Oil: Biological Properties, Health Benefits and Commercial Applications. Nova Science Publishers, Inc. 2014. p. 131-148